selectively targets interleukin-17A, provides rapid and sustained clearance of moderate-to-severe psoriasis. The objective of this study was to evaluate the efficacy of secukinumab on moderate-to-severe psoriasis affecting the head and neck. The safety and overall efficacy of secukinumab in patients with moderate-to-severe psoriasis will be described. 
INTRODUCTION
The head (including the scalp and face) and neck are the body areas most commonly affected by psoriasis, and, in many cases, the most difficult areas to treat [1] [2] [3] . Scalp psoriasis is estimated to affect between 40% and 90% of individuals with psoriasis, and facial psoriasis has been reported by 17-29% of adults with psoriasis [2, 4] . In addition to physical symptoms of itching, pain, lesion cracking, and bleeding that may cause discomfort and reduced quality of life, individuals with extensive and highly visible psoriasis affecting areas such as the head and neck can experience higher psychological burdens [2, 5, 6] . Symptoms of psoriasis can cause patients to face social stigmatization that results in embarrassment, shame, and stress [7] . Visible psoriasis can also negatively affect work or school attendance and performance, reduce self-confidence, and interfere with daily routines [2, 8] .
The disease burden in patients with head and neck psoriasis is substantial. Patients with facial psoriasis have significantly greater whole body Psoriasis Severity Area Index (PASI) scores than patients without facial involvement (15.6 vs. 6.9; P\0.05) and facial psoriasis is associated with longer disease duration and younger age of onset [9, 10] . Quality of life is more negatively impacted in women with scalp psoriasis, and many individuals with scalp psoriasis report being inconvenienced by caring for their scalp [11, 12] . Additionally, scalp psoriasis has been shown to impair physical and psychological health regardless of the severity of psoriasis on other body regions [13] .
Secukinumab is a human monoclonal antibody that selectively binds to and neutralizes interleukin (IL)-17A, a key cytokine in the pathogenesis of psoriasis [14] . The safety and efficacy of secukinumab has previously been demonstrated in phase 3 studies of patients with moderate-to-severe plaque psoriasis [15] [16] [17] [18] . In this report, 52-Week results were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe psoriasis, and efficacy was evaluated for (1) head and neck (HN)PASI subscores and (2) whole body composite PASI scores. Subcomponent PASI results for the trunk, upper limbs, and lower limbs are reported separately in this publication by Menter et al. [19] .
METHODS

Study Design
Data were pooled from four randomized, The design of these trials has been previously reported in detail [15] [16] [17] . Briefly, secukinumab or placebo was administered at Baseline, Weeks 1, 2 and 3, and then every 4 weeks from Week 4 to 48.
At Week 12, patients receiving placebo were randomized to secukinumab. Secukinumab was administered by subcutaneous injection; in ERASURE and FIXTURE the lyophilisate in vial formulation was used, in FEATURE a prefilled syringe was used, and in JUNCTURE an autoinjector was used.
Study Population
Male and female patients (C18 years of age) with moderate-to-severe plaque psoriasis of C6 months' duration that was poorly controlled by topical treatments, phototherapy, and/or previous systemic therapy were considered eligible for the study population. Moderate-to-severe plaque psoriasis was defined as Baseline PASI score C12, Investigator's Global Assessment modified 2011 (IGA mod 2011) [20] score C3, and total body surface area (BSA) affected C10%. Exclusion criteria included active, ongoing inflammatory diseases; active, 
Efficacy and Safety Assessments
RESULTS
Patient Demographics
Treatment groups were well balanced for demographic and Baseline disease characteristics in the overall study population ( (Fig. 1) . A 50% reduction in mean HNPASI score occurred after 2.0 weeks (95% confidence interval [CI] 1.9, 2.2) with secukinumab 300 mg and after 2.7 weeks (95% CI 2.6, 2.9) with secukinumab 150 mg (Fig. 2) .
Whole Body Efficacy
Pooled efficacy responses through Week 52 from these four phase 3 trials are presented in Fig. 3 . In the overall pooled study population, secukinumab provided rapid skin clearance with responses being observed as early as Week 1. Initial responses were maintained to Week 52 and the greatest benefit was observed with secukinumab 300 mg. At Week 52, PASI 90 and PASI 100 were achieved by 68.1% and 40.8% of patients receiving secukinumab 300 mg, respectively, and by 47.6% and 24.3% of patients receiving secukinumab 150 mg, respectively. Results are for the full analysis set of patients BMI body mass index, BSA body surface area, IGA investigator's global assessment, PASI psoriasis area and severity index, SD standard deviation a n = 688 for secukinumab 300 mg, n = 692 for secukinumab 150 mg b n = 690 for secukinumab 300 mg Treatment with secukinumab also showed rapid and significant improvement in quality of life as measured by DLQI. At Week 12, DLQI scores of 0 or 1 were achieved by 58.8% of patients receiving secukinumab 300 mg and 50.1% of patients receiving secukinumab 150 mg. Improvements in DLQI continued to Week 52 with DLQI scores of 0 or 1 being achieved by 67.9% and 53.7% of patients receiving secukinumab 300 mg and secukinumab 150 mg, respectively. Mean decreases (improvements) in DLQI from Baseline to Week 52 were -11.0 with secukinumab 300 mg and -9.2 with secukinumab 150 mg, and these responses surpassed the C5-point reduction in DLQI required for a minimal clinically important difference in patients with psoriasis that are receiving biologic therapy [23] .
Safety
Secukinumab demonstrated a favorable safety profile in the overall pooled study population, and the rates of AEs were similar between the 300 and 150 mg doses (Table 2) . Through Week 52, AEs were reported in 83.3% of patients receiving secukinumab 300 mg and in 81.2% of patients receiving secukinumab 150 mg. The most common AEs for both secukinumab doses were nasopharyngitis (23.7-24.9%), headache (9.4-11.4%), diarrhea (6.5-7.8%), and upper respiratory tract infection (7.7-9.2%). Serious n represents the number of evaluable subjects. HNPASI 75/90/100, 75%/90%/100% improvement from Baseline head and neck psoriasis area and severity index scores 
DISCUSSION
The efficacy of secukinumab 300 mg and secukinumab 150 mg was previously demonstrated to be superior to placebo (in ERASURE, FIXTURE, FEATURE, and JUNCTURE) and etanercept (in FIXTURE) at Week 12 [15] [16] [17] . Results from this pooled analysis of four phase 3 trials show that secukinumab is effective for the treatment of moderate-to-severe psoriasis affecting the head and neck, and the whole body. Secukinumab therapy resulted in rapid improvement of psoriasis on the head and neck. Improvements were observed as early as Week 1 at which point secukinumab 300 mg provided an approximate 25% reduction in mean HNPASI score from Baseline. Disease clearance continued to increase on the head and neck after the first Week, and patients experienced a 50% reduction in mean HNPASI score after 2.0 weeks of treatment with secukinumab 300 mg. Improvement in psoriasis affecting the head and neck were maintained through Week 52, with the greatest benefit seen in patients receiving secukinumab 300 mg (Fig. 1) .
The efficacy and safety of secukinumab was consistent across all four phase 3 trials that were pooled for this analysis. Results from this study are also consistent with findings from other studies that evaluated the efficacy of biologic Results are for the safety set of patients. Safety results are only presented to Week 12 for placebo because at Week 12, patients receiving placebo were randomized to secukinumab agents by body region [24] [25] [26] . In these studies, along with the findings reported here, head and neck plaque psoriasis generally responded favorably, rapidly, and significantly to biologic treatment. Conversely, psoriasis on the head and neck does not typically respond well to conventional systemic therapies, and topical therapies can be burdensome to apply resulting in low adherence [26, 27] . This study was limited by the inability to differentiate between affected areas of the head and neck (e.g., scalp vs face psoriasis) because PASI does not allow for differentiation of specific regions of the head and neck. A study is currently ongoing that will evaluate the efficacy of secukinumab on scalp psoriasis, and results from this trial will provide further data on the treatment of this difficult to manage area [28] . Additionally, there was no control group after Week 12.
Results of this pooled analysis demonstrate that secukinumab is an effective and well-tolerated treatment for plaque psoriasis of the head and neck. The majority of the patients treated with secukinumab 300 mg achieved almost clear or clear skin as indicated by high HNPASI 90 and HNPASI 100 response rates. Secukinumab also provided robust overall efficacy. At Week 12, PASI 75 response rates were similar between the head and neck region and the whole body. A larger proportion of patients receiving secukinumab 300 mg achieved HNPASI 90 and HNPASI 100 (73.3% and 61.1%, respectively) response rates at Week 12 than achieved composite PASI 90 and PASI 100 (59.6% and 29.0%, respectively) response rates over the same time period. These findings indicate that patients achieve complete or almost complete clearance of psoriasis on the head and neck at a quicker rate than on the whole body following treatment with secukinumab. Likewise, 
CONCLUSION
Pooled results of four phase 3 studies of secukinumab showed robust and sustained efficacy in treating psoriasis affecting both the head and neck and the whole body. 
